1. The SOMCT03 phase 2 clinical trial is ongoing and registered in the EudraCT database.
2. The trial is sponsored by SOM Innovation Biotech SA and aims to assess the efficacy and safety of two doses of SOM3355 in patients with Huntington's Disease.
3. The IMP used in the trial is bevantolol hydrochloride, which has a marketing authorization and will be administered orally in capsule form.
The article provides information on a phase IIb clinical trial for SOM3355, a potential treatment for Huntington's Disease with choreic movements. The trial is sponsored by SOM Innovation Biotech SA and is being conducted in Spain under the oversight of the AEMPS.
The article presents detailed information on the protocol, sponsor, and IMP identification for the trial. However, it does not provide any information on the potential risks or side effects associated with SOM3355. Additionally, there is no discussion of any potential biases or conflicts of interest that may exist due to the sponsorship of the trial by SOM Innovation Biotech SA.
Furthermore, while the article provides information on the study design and population of trial subjects, it does not discuss any potential limitations or weaknesses in the study design that may impact the validity of its results. There is also no mention of any alternative treatments or therapies currently available for Huntington's Disease with choreic movements.
Overall, while the article provides useful information on a clinical trial for a potential treatment for Huntington's Disease with choreic movements, it lacks critical analysis and discussion of important considerations such as potential risks and limitations in study design.